查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947945

补体抑制剂市场依产品类型、适应症、给药途径、通路和最终用户划分，全球预测（2026-2032年）

Complement Inhibitors Market by Product Type, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

补体抑制剂市场预计到 2025 年将达到 139.4 亿美元，到 2026 年将成长到 152.2 亿美元，到 2032 年将达到 269.1 亿美元，年复合成长率为 9.84%。

关键市场统计数据
基准年 2025 139.4亿美元
预计年份：2026年 152.2亿美元
预测年份 2032 269.1亿美元
复合年增长率 (%) 9.84%

补体抑制剂策略架构：重点在于相关人员的科学进展、临床差异化和跨职能优先事项

补体抑制剂处于免疫学、神经病学、肾臟病学和罕见疾病治疗的交叉领域，代表着一个动态发展的治疗领域，其发展受到精准生物学和标靶递送技术创新的推动。近年来，高品质临床证据的累积、监管核准的不断扩大以及多种给药方式的开发，共同提升了生物製药开发商、支付方和专科医疗机构的策略关注度。随着各公司不断完善作用机制，并透过便捷的给药方式、安全性以及给药途径实现差异化，竞争格局日益取决于临床差异化和卓越的运营，而非单一产品的优势。

补体抑制疗法中不断发展的治疗模式、递送创新和临床整合将如何重塑研发和商业化策略

补体抑制剂领域正经历变革性的转变，这主要得益于给药方式多样化、递送技术创新以及补体生物学临床应用的拓展。单株抗体不断改进，以延长半衰期并降低免疫抗原性；同时，胜肽、 RNA干扰疗法和小分子药物也不断丰富全身性和标靶性补体调节的工具库。这种给药方式的转变正在改变药物研发模式，使得更灵活的给药方案和替代给药途径成为可能，这对于慢性疾病的治疗和提高患者依从性尤其重要。

评估2025年美国关税趋势对补体抑制剂供应韧性、筹资策略和商业化路径的影响

贸易政策趋势和关税措施将对整个医药价值链产生多层次的影响，而2025年美国关税的累积效应很可能波及补体抑制剂的采购、生产和分销管道。由于生物製药和小分子药物的许多原料、关键试剂和特殊成分都依赖全球采购，进口成本上升和物流中断可能会促使製造商重新评估其供应商所在地和库存策略。这可能导致近岸外包和双重采购策略的加速推进，旨在降低贸易摩擦的风险，同时维持供应的连续性。

详细的細項分析揭示了产品形态、治疗适应症、给药途径、分销管道和终端用户环境如何相互作用，从而影响策略制定。

深入了解产品类型、临床适应症、给药途径、分销管道和终端用户环境之间的相互作用，对于制定研发和商业策略至关重要。依产品类型划分，市场涵盖单株抗体、胜肽、 RNA干扰疗法和小分子药物。单株抗体包括传统药物和长效药物，例如已上市的补体抑制剂抗体和新一代工程变体。肽类药物包含具有不同药物动力学特征的标靶抑制剂。 RNA干扰疗法着重于肝臟和全身通路调控。小分子药物提供口服或辅助治疗方案，其生产和定价机制各不相同。对于单株抗体而言，速效和长效药物之间的差异会影响其临床应用以及静脉给药的可能性。

区域趋势与策略意义：了解美洲、欧洲、中东和非洲以及亚太地区的环境将如何影响临床应用和进入途径

区域趋势反映了不同地区法规环境、医疗服务模式和相关人员期望的差异，这些差异对补体抑制剂的研发、上市和应用产生了重大影响。在美洲，重点在于创新成果的商业化和与支付方的谈判，临床网络和专科医疗中心促进了药物准入途径的建立和真实世界证据的生成。同时，欧洲、中东和非洲的监管和报销环境各不相同，各国特定的卫生技术评估流程和区域采购惯例实践要求制定量身定制的准入策略并儘早与支付方接洽。在亚太地区，快速发展的医疗基础设施、新兴的专科医疗中心以及对本地生产和临床研究能力的不断增长的投资共同塑造了市场动态。

竞争格局评估揭示了现有企业、创新新参与企业、製造合作伙伴和支付方如何塑造差异化和市场动态。

补体抑制剂领域的竞争格局由两类企业组成：一类是拥有临床验证资产的成熟开发商，另一类是推出差异化疗法和给药途径的新创企业。已证实具有临床疗效的现有计画在安全性和持久性方面树立了高标准，而创新者则专注于透过改善给药途径、减轻治疗负担和拓展适应症来满足未被满足的医疗需求。伙伴关係与授权协议仍然是加速分子开发和商业性扩张的关键，策略联盟的建立旨在整合临床专长、生产能力和市场进入资源。

为确保永续优势，提出整合科学差异化、供应链韧性和以支付方为中心的实证项目的实用策略建议。

产业领导者应采取整合策略，加速临床差异化，同时增强营运韧性并加强与支付方的合作。首先，优先对治疗方法多样性和灵活的给药方式进行策略性投资，以减轻治疗负担并扩大服务点。其次，推广以生物标记主导的项目和务实的试验设计，以加快获得可操作证据的速度，并支持有针对性的报销谈判。第三，在需求出现之前，投资供应链冗余、本地製造伙伴关係以及库存策略，以降低受贸易政策和物流中断的影响。

一种透明且可重复的混合方法调查方法，结合了专家访谈、系统文献综述和三角验证技术，以得出可操作的研究结果。

本报告整合了多种研究方法，以确保其稳健性、可靠性和实用性。主要研究包括对临床意见领袖、商业高管、生产专家和支付方进行深入访谈，以收集有关临床实践、准入趋势和营运限制的最新见解。次要研究包括对同行评审文献、监管文件、临床指南和公司披露资讯进行系统性回顾，以阐明主要研究结果并检验技术假设。资料三角测量法整合了定量和定性讯息，以调和相互衝突的观点并突出共识趋势。

将科学创新、运作韧性和实证准入策略相结合的整体性综合方法是补体抑制剂疗法成功的先决条件。

总之，补体抑制剂正从一个利基治疗领域向一个多方面治疗领域转型，其治疗方式多样，适应症不断扩大，给药模式也在不断演变，这些变化共同带来了巨大的机会和运作上的复杂性。抗体工程、胜肽设计、 RNA干扰和小分子化学领域的科学进步正在创造差异化的临床特征，而给药和分销方式的改变则有助于扩大临床覆盖范围并实现以患者为中心的模式。同时，供应链的脆弱性、贸易政策的不确定性以及支付方的严格审查都要求我们积极主动地进行风险管理，并进行基于循证医学的价值沟通。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章补体抑制剂市场（依产品类型划分）

  • 单株抗体
    • Eculizumab
    • Ravulizumab
  • 胜肽
  • RNAi疗法

第九章补体抑制剂市场依适应症划分

  • 非典型溶血性尿毒症候群
    • 成年患者
    • 儿童患者
  • 重症肌无力
    • 系统
    • 眼球型
  • 视神经脊髓炎频谱障碍
    • AQP4 阴性
    • AQP4阳性
  • 阵发性睡眠性血尿症
    • 成年患者
    • 儿童患者

第十章补体抑制剂市场依给药途径划分

  • 静脉注射
  • 口服
  • 皮下注射

第十一章补体抑制剂市场依分销管道划分

  • 在线的
  • 离线

第十二章补体抑制剂市场（依最终用户划分）

  • 居家医疗
  • 医院
  • 专科诊所
    • 肾臟病诊所
    • 神经病学中心

第十三章补体抑制剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章补体抑制剂市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国补体抑制剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国补体抑制剂市场

第十七章：中国补体抑制剂市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • Eli Lilly and Company
  • Horizon Therapeutics plc
  • Ionis Pharmaceuticals, Inc.
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Sanofi
  • UCB SA
Product Code: MRR-4F7A6D4FB69B

The Complement Inhibitors Market was valued at USD 13.94 billion in 2025 and is projected to grow to USD 15.22 billion in 2026, with a CAGR of 9.84%, reaching USD 26.91 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.94 billion
Estimated Year [2026] USD 15.22 billion
Forecast Year [2032] USD 26.91 billion
CAGR (%) 9.84%

A strategic framing of complement inhibitors highlighting scientific advances, clinical differentiation, and cross-functional priorities for stakeholders

Complement inhibitors are at the intersection of immunology, neurology, nephrology, and rare disease therapeutics, representing a dynamically evolving class shaped by precision biology and targeted delivery innovations. Recent years have seen the convergence of high-quality clinical evidence, expanded regulatory approvals, and diversified modality development that collectively have elevated strategic interest from biopharma developers, payers, and specialist providers. As companies refine mechanisms of action and differentiate through dosing convenience, safety profiles, and administration routes, the competitive landscape is increasingly defined by clinical differentiation and operational excellence rather than single-asset dominance.

Moreover, ongoing advances in biomarker science and patient stratification are enabling more precise indication targeting, which, in turn, is reshaping trial design and commercial access approaches. Concurrently, payers and health systems are emphasizing value-based care and outcomes measurement, prompting developers to incorporate health economics into clinical programs earlier. Given these convergent forces, stakeholders must navigate complex regulatory pathways, supply chain imperatives, and payer expectations while capitalizing on opportunities to expand into adjacent indications and alternative care settings. Ultimately, the therapeutic promise of complement inhibition depends not only on clinical efficacy but also on strategic alignment across development, commercialization, and delivery systems.

How evolving modalities, delivery innovations, and clinical integration are reshaping development and commercialization strategies across complement inhibition therapies

The landscape for complement inhibitors is undergoing transformative shifts driven by advances in modality diversity, delivery innovation, and expanded clinical application of complement biology. Monoclonal antibodies continue to be refined for improved half-life and reduced immunogenicity, while peptides, RNA interference therapeutics, and small molecules are broadening the toolkit for both systemic and targeted complement modulation. These modality shifts are changing development paradigms, enabling more flexible dosing regimens and alternative routes of administration, which are especially important for chronic indications and for improving patient adherence.

At the same time, clinical practice is adapting as neurologists, nephrologists, and hematologists incorporate new therapeutic options that change patient pathways and care settings. Real-world evidence initiatives and post-authorization data collection are informing optimized positioning and reimbursement conversations. In addition, the industry is witnessing a maturation of commercial strategies where lifecycle planning, combination approaches, and label expansion are central to sustaining therapeutic relevance. Taken together, these shifts create a landscape where scientific progress and pragmatic commercialization strategies converge, compelling organizations to re-evaluate partnerships, manufacturing footprints, and evidence-generation plans to sustain competitiveness.

Assessing how 2025 United States tariff developments can influence supply resilience, sourcing strategies, and commercialization pathways for complement inhibitors

Trade policy developments and tariff actions can create multilayered impacts across pharmaceutical value chains, and the cumulative effect of United States tariff measures in 2025 is likely to reverberate through sourcing, manufacturing, and distribution channels for complement inhibitors. Because many raw materials, critical reagents, and specialized components for biologics and small molecules are globally sourced, increased import costs or logistical disruptions can prompt manufacturers to reassess supplier footprints and inventory strategies. In turn, this can accelerate nearshoring or dual-sourcing initiatives aimed at reducing exposure to trade frictions while preserving continuity of supply.

Furthermore, tariff-induced cost pressures often lead to shifts in procurement priorities and contract negotiations, prompting contract manufacturers and suppliers to renegotiate terms or pass costs through to downstream stakeholders. For developers of next-generation modalities such as RNA interference therapeutics and novel peptides, where supply chains can be highly specialized, even modest trade barriers can increase complexity in batch release timelines and regulatory filings. As a consequence, organizations may prioritize supply-chain resilience, increase investment in domestic manufacturing capacity, or revise clinical supply strategies to protect trial integrity.

Regulatory agencies and payers may also respond to tariff-driven cost dynamics by scrutinizing pricing and reimbursement frameworks more closely, which could affect market access and formulary positioning. Therefore, companies should view tariff impacts as a catalyst to enhance operational agility, strengthen supplier relationships, and integrate trade-policy scenarios into risk-management frameworks that inform both short-term tactical moves and long-term strategic planning.

Detailed segmentation insights revealing how product modalities, therapeutic indications, administration routes, distribution channels, and end-user settings converge to shape strategy

A granular understanding of how product types, clinical indications, routes of administration, distribution channels, and end-user settings interact is essential for shaping development and commercial strategies. For product type, the market spans monoclonal antibodies, peptides, RNA interference therapeutics, and small molecules, where monoclonal antibodies include legacy and long-acting agents such as established complement-blocking antibodies and next-generation engineered variants, peptides encompass targeted inhibitors with distinct pharmacokinetic profiles, RNAi therapeutics focus on hepatic and systemic pathway modulation, and small molecules offer oral or adjunctive options with different manufacturing and pricing dynamics. Within monoclonal antibodies, differentiation between rapidly acting and extended-interval agents influences clinic utilization and infusion capacity.

Across indications, therapies address a spectrum that includes atypical hemolytic uremic syndrome, myasthenia gravis, neuromyelitis optica spectrum disorder, and paroxysmal nocturnal hemoglobinuria, each with unique diagnostic complexity and patient management models. Subpopulations such as adult versus pediatric patients, generalized versus ocular manifestations, and seropositive versus seronegative cohorts necessitate tailored clinical evidence and access strategies. Route of administration is another axis of differentiation: intravenous delivery remains central to hospital- and clinic-based infusion models, oral formulations enable home administration and improved adherence, and subcutaneous options support clinic-based or self-administration paradigms that reduce healthcare resource utilization. Distribution channels further shape commercialization tactics, with hospital pharmacies supporting inpatient and outpatient infusion, online pharmacies enabling direct-to-patient logistics, and retail pharmacies serving chain and independent dispensing networks. Finally, end users span home care, hospitals, and specialty clinics, where home care may involve caregiver or self-administration, hospitals deliver complex inpatient care, and specialty clinics such as nephrology and neurology centers manage long-term treatment programs. Integrating these segmentation dimensions reveals how clinical, operational, and commercial choices must be coordinated to support patient access and product differentiation.

Regional dynamics and strategic implications illustrating how Americas, Europe Middle East & Africa, and Asia-Pacific environments influence clinical adoption and access pathways

Regional dynamics reflect distinct regulatory environments, healthcare delivery models, and stakeholder expectations that materially influence how complement inhibitors are developed, launched, and adopted. In the Americas, there is a strong emphasis on innovation commercialization and payer negotiation, with clinical networks and specialist centers facilitating access pathways and real-world evidence generation. Conversely, Europe, Middle East & Africa exhibits heterogeneous regulatory and reimbursement landscapes where country-specific health technology assessment processes and regional procurement practices demand tailored access strategies and early payer engagement. In Asia-Pacific, market dynamics are shaped by a mix of rapidly developing healthcare infrastructure, emerging specialist centers, and increasing investment in local manufacturing and clinical research capacity.

Moreover, cross-region differences in clinical practice patterns and diagnostic infrastructure affect patient identification and pathway design, while variations in reimbursement philosophies influence pricing and contracting approaches. Because these regional factors evolve in response to policy shifts, demographic trends, and local innovation ecosystems, organizations must align regulatory strategies, evidence generation plans, and commercial operations with regional priorities. By doing so, developers and commercial teams can optimize launches, design phased entry strategies, and allocate resources to maximize clinical impact and patient access across diverse geographic markets.

Competitive landscape assessment highlighting how incumbents, innovative entrants, manufacturing partners, and payers shape differentiation and market dynamics

Competitive dynamics in complement inhibition are defined by a mix of established developers with clinically validated assets and emerging players introducing differentiated modalities and delivery approaches. Incumbent programs with proven clinical outcomes set high bars for safety and durability, while innovators focus on addressing unmet needs through improved administration routes, reduced treatment burden, and expanded indication footprints. Partnerships and licensing deals continue to be central to accelerating molecule advancement and scaling commercial operations, with strategic alliances often formed to combine clinical expertise, manufacturing capacity, and market access capabilities.

Additionally, contract manufacturing organizations and specialized suppliers play critical roles in enabling commercial scale-up, and their capabilities often determine the feasibility and timing of alternative dosing strategies or new presentations. Meanwhile, payer and provider stakeholders increasingly demand robust comparative effectiveness data and long-term safety evidence, shaping the competitive playbook for second-generation agents. Collectively, these forces create a competitive environment where differentiation is driven by clinical value, operational readiness, and the ability to demonstrate measurable patient and system benefits over time.

Actionable strategic recommendations for leaders to align scientific differentiation, supply resilience, and payer-focused evidence programs for sustained advantage

Industry leaders should adopt an integrated playbook that accelerates clinical differentiation while strengthening operational resilience and payer engagement. First, prioritize strategic investments in diversified modalities and flexible delivery formats that reduce treatment burden and expand care settings. Second, advance biomarker-driven programs and pragmatic trial designs that shorten time to actionable evidence and support targeted reimbursement discussions. Third, invest ahead of demand in supply-chain redundancy, local manufacturing partnerships, and inventory strategies that mitigate exposure to trade policy and logistical disruptions.

In parallel, commercial teams must develop tailored access strategies aligned with regional payer expectations and clinician workflows, incorporating real-world evidence capture and outcomes-based contracting where appropriate. Collaboration is also essential: pursue targeted alliances to fill capability gaps, accelerate launches, or share development risk. Finally, embed health economics and outcomes research into clinical programs from the outset to facilitate formulary negotiations and to articulate value propositions convincingly. By executing a cohesive approach that blends scientific innovation with operational and commercial rigor, organizations can create sustainable advantages and improve patient access across therapeutic and geographic domains.

Transparent and reproducible mixed-methods research methodology combining expert interviews, systematic literature review, and triangulation for actionable intelligence

This report synthesizes multiple research approaches to ensure robustness, credibility, and practical relevance. Primary research consisted of in-depth interviews with clinical thought leaders, commercial executives, manufacturing experts, and payers, which provided contemporaneous perspectives on clinical practice, access dynamics, and operational constraints. Secondary research involved systematic review of peer-reviewed literature, regulatory documents, clinical guidelines, and company disclosures to contextualize primary findings and validate technical assumptions. Data triangulation integrated quantitative and qualitative inputs to reconcile divergent viewpoints and to highlight consensus trends.

Analytical methods included thematic coding of interview transcripts, comparative policy analysis across regulatory jurisdictions, and scenario planning to surface potential impacts of supply-chain and trade-policy developments. The methodology emphasized transparency and reproducibility, with source attribution for key claims and clearly documented inclusion criteria for secondary sources. Limitations were addressed through sensitivity checks and by incorporating multi-stakeholder perspectives to reduce bias. Taken together, this mixed-methods approach yields actionable intelligence that supports both strategic decision-making and operational execution.

Concluding synthesis that connects scientific innovation, operational resilience, and evidence-based access strategies as imperatives for success in complement inhibition

In summary, complement inhibitors are transitioning from a niche therapeutic category into a diversified class with multiple modalities, expanded indications, and evolving delivery paradigms that together present significant opportunities and operational complexities. Scientific advances in antibody engineering, peptide design, RNA interference, and small-molecule chemistry are creating differentiated clinical profiles, while shifts in administration and distribution enable broader care settings and patient-centric models. At the same time, supply-chain fragility, trade-policy uncertainty, and payer scrutiny demand proactive risk management and evidence-based value communication.

Consequently, organizations that align scientific innovation with robust manufacturing strategies, targeted evidence generation, and regionally adapted commercialization plans will be best positioned to translate clinical promise into sustainable clinical uptake. Strategic partnerships, early payer engagement, and investments in real-world data infrastructure will further enhance competitive positioning. Ultimately, success in this evolving ecosystem requires an integrated approach that balances short-term operational resilience with long-term investment in clinical differentiation and patient-centric access solutions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Complement Inhibitors Market, by Product Type

  • 8.1. Monoclonal Antibody
    • 8.1.1. Eculizumab
    • 8.1.2. Ravulizumab
  • 8.2. Peptide
  • 8.3. Rnai Therapeutic

9. Complement Inhibitors Market, by Indication

  • 9.1. Atypical Hemolytic Uremic Syndrome
    • 9.1.1. Adult Patients
    • 9.1.2. Pediatric Patients
  • 9.2. Myasthenia Gravis
    • 9.2.1. Generalized
    • 9.2.2. Ocular
  • 9.3. Neuromyelitis Optica Spectrum Disorder
    • 9.3.1. Aqp4 Negative
    • 9.3.2. Aqp4 Positive
  • 9.4. Paroxysmal Nocturnal Hemoglobinuria
    • 9.4.1. Adult Patients
    • 9.4.2. Pediatric Patients

10. Complement Inhibitors Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Complement Inhibitors Market, by Distribution Channel

  • 11.1. Online
  • 11.2. Offline

12. Complement Inhibitors Market, by End User

  • 12.1. Home Care
  • 12.2. Hospitals
  • 12.3. Specialty Clinics
    • 12.3.1. Nephrology Clinics
    • 12.3.2. Neurology Centers

13. Complement Inhibitors Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Complement Inhibitors Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Complement Inhibitors Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Complement Inhibitors Market

17. China Complement Inhibitors Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie Inc.
  • 18.6. Alexion Pharmaceuticals, Inc.
  • 18.7. Amgen Inc.
  • 18.8. Apellis Pharmaceuticals, Inc.
  • 18.9. AstraZeneca PLC
  • 18.10. Biogen Inc.
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Bristol Myers Squibb Company
  • 18.13. Catalyst Biosciences, Inc.
  • 18.14. Eli Lilly and Company
  • 18.15. Horizon Therapeutics plc
  • 18.16. Ionis Pharmaceuticals, Inc.
  • 18.17. Janssen Pharmaceuticals, Inc.
  • 18.18. Merck & Co., Inc.
  • 18.19. Novartis AG
  • 18.20. Pfizer Inc.
  • 18.21. Regeneron Pharmaceuticals, Inc.
  • 18.22. Roche Holding AG
  • 18.23. Sanofi
  • 18.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPLEMENT INHIBITORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPLEMENT INHIBITORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ECULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ECULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ECULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RAVULIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RAVULIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RAVULIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEPTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEPTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEPTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RNAI THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RNAI THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY RNAI THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GENERALIZED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GENERALIZED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GENERALIZED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 NEGATIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 NEGATIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 NEGATIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 POSITIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 POSITIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY AQP4 POSITIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEPHROLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEPHROLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEPHROLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROLOGY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 207. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 208. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 209. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 211. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 212. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 214. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GCC COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 243. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 244. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 245. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 247. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 248. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 250. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. G7 COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 255. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 256. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 257. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 259. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 260. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 262. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL COMPLEMENT INHIBITORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA COMPLEMENT INHIBITORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY MONOCLONAL ANTIBODY, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY ATYPICAL HEMOLYTIC UREMIC SYNDROME, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY MYASTHENIA GRAVIS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY NEUROMYELITIS OPTICA SPECTRUM DISORDER, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY PAROXYSMAL NOCTURNAL HEMOGLOBINURIA, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA COMPLEMENT INHIBITORS MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)